ArQule and Camitro in merger

Published: 3-Feb-2001


Massachusetts-based drug discovery specialist ArQule is to merge with Californian predictive modelling company Camitro. Based in Menlow Park, CA, US, Camitro uses in silico modelling to determine the ADMET (absorption, distribution, metabolism, elimination, toxicity) properties of drugs; ArQule sees this as an important fit with its small molecule design and high-throughput automated synthesis capability. 'This allows both companies to reach a common goal that would have taken us 2–3 years to achieve independently,' comments Camitro chief executive Barry Selick.

You may also like